- Home
- WLY vs ZLAB Comparison
WLY vs ZLAB Comparison
Compare WLY & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLY
- ZLAB
- Stock Information
- Founded
- WLY 1807
- ZLAB 2013
- Country
- WLY United States
- ZLAB China
- Employees
- WLY N/A
- ZLAB N/A
- Industry
- WLY Books
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- WLY Consumer Discretionary
- ZLAB Health Care
- Exchange
- WLY Nasdaq
- ZLAB Nasdaq
- Market Cap
- WLY 2.1B
- ZLAB 3.6B
- IPO Year
- WLY N/A
- ZLAB 2017
- Fundamental
- Price
- WLY $44.70
- ZLAB $35.00
- Analyst Decision
- WLY
- ZLAB Buy
- Analyst Count
- WLY 0
- ZLAB 5
- Target Price
- WLY N/A
- ZLAB $54.28
- AVG Volume (30 Days)
- WLY 626.3K
- ZLAB 1.0M
- Earning Date
- WLY 06-17-2025
- ZLAB 08-05-2025
- Dividend Yield
- WLY 3.12%
- ZLAB N/A
- EPS Growth
- WLY N/A
- ZLAB N/A
- EPS
- WLY 1.53
- ZLAB N/A
- Revenue
- WLY $1,677,609,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- WLY $1.75
- ZLAB $44.07
- Revenue Next Year
- WLY $2.40
- ZLAB $49.13
- P/E Ratio
- WLY $29.50
- ZLAB N/A
- Revenue Growth
- WLY N/A
- ZLAB 43.72
- 52 Week Low
- WLY $36.50
- ZLAB $16.01
- 52 Week High
- WLY $53.96
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- WLY 67.61
- ZLAB 51.28
- Support Level
- WLY $42.90
- ZLAB $34.44
- Resistance Level
- WLY $44.33
- ZLAB $38.18
- Average True Range (ATR)
- WLY 1.37
- ZLAB 1.33
- MACD
- WLY 0.80
- ZLAB -0.44
- Stochastic Oscillator
- WLY 94.42
- ZLAB 17.66
About WLY John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.